Browsed by
Tag: Operations

SolarWindow Expands U.S. Operations to Asia and Strengthens Management Team

SolarWindow Expands U.S. Operations to Asia and Strengthens Management Team

SolarWindow Technologies, Inc. (Symbol: WNDW), developer of transparent electricity-generating coatings for glass and plastics, today announced corporate expansion of its US operations through newly established commercial development offices in South Korea, repeatedly ranked number one in the worldwide Bloomberg Innovation Index and a leading country in advanced manufacturing of new technologies and products.

This press release features multimedia. View the full release here:

Alexandra Musk, Associate VP, Brand & Business Development,SolarWindow Technologies, Inc. (Photo: Business Wire)

“Only a few weeks ago, we demonstrated our largest and most transparent SolarWindow™ glass panes generating electricity from sunlight and artificial indoor light,” stated Mr. Jay S. Bhogal, CEO and President of SolarWindow. “This milestone achievement spurred today’s expansion of our operations and cross-functional business teams in the United States and Korea.”

The Company’s newly formed Asia business unit with its strategic hires and expanded operations places SolarWindow in a geography that is home to some of the world’s most advanced-technology manufacturers of next-generation building materials, electric vehicles and commercial transportation systems, and consumer electronics — a natural fit with the Company’s proprietary LiquidElectricity™ coatings for films, glass, and plastics.

“With this expansion, SolarWindow taps into high tech manufacturing in new markets while strengthening our position as a Made-in-America energy solution with global implications,” continued Mr. Bhogal. “With rising global demand for efficient, sustainable, and cost-competitive solutions, now is the time to apply our proprietary clean energy source — the application of our LiquidElectricity™ coatings — to flat window glass and to products far beyond.”

Bridging US & Asia Business Development: Ms. Alexandra Musk

Bridging U.S. and Asian SolarWindow offices is newly appointed Associate VP Brand & Business Development, Ms. Alexandra Musk, who brings a family legacy of innovative, sustainable ventures in renewable energy and electric vehicles.

Based in California, Ms.

Read the rest
CrystalGenomics Appoints Gavin Choy, as President, CG Pharmaceuticals, Inc. to Lead Pipeline Expansion and Global Operations

CrystalGenomics Appoints Gavin Choy, as President, CG Pharmaceuticals, Inc. to Lead Pipeline Expansion and Global Operations

SEOUL, South Korea, Oct. 7, 2020 /PRNewswire/ — CrystalGenomics, Inc. (KOSDAQ: 083790), a commercial stage biopharmaceutical company that is dedicated to the discovery, development and commercialization of novel therapeutics in unmet medical need areas of inflammation, oncology, and infectious disease, today announced the appointment of Gavin Choy, PharmD, MBA as President of CG Pharmaceuticals, Inc., CrystalGenomics’ subsidiary focused on the clinical development of novel therapeutics. Dr. Choy most recently served as Chief Operating Officer at Apollomics, Inc.

“As a senior leader in multiple prior biotech companies and a scientific or operational advisor of several others, Gavin has extensive experience in leading biotech innovation from early stage research through commercialization of therapies. His significant insights will be invaluable to CrystalGenomics as we advance our pipeline assets for the potential treatment of a broad range of diseases and seek additional assets to develop,” said Dr. Joong Myung Cho, Chairman, CG Pharmaceuticals and CrystalGenomics.

Gavin Choy, PharmD, MBA

Dr. Choy brings to CrystalGenomics a proven track record in drug development and global development operations. He has led cross functional teams in areas of clinical research, development operations, biometrics, pharmacovigilance, project and alliance management, medical writing, field liaisons, clinical pharmacology, IT, legal, and public relations in therapeutic areas of infectious disease, hematology and oncology, immuno-oncology, and vaccines. Through design and leading the formation of high-performing teams, Dr. Choy has built successful global organizations leading to the advancement of pipeline assets, multiple INDs and commercialized drug products. Dr. Choy has designed corporate strategies leading to successful financings and instrumental in in-licensing opportunities at prior organizations. Dr. Choy received a doctorate in pharmacy from the University of Southern California, completed post-doctorate training at the Department of Veteran Affairs, and holds a Health Care focused Master of Business Administration from the Paul Merage School of Business, University

Read the rest